Our Pipeline
At Iktos, our unique approach leverages cutting-edge AI and robotics to advance drug discovery projects rapidly. Our innovative technologies, Generative AI, Synthesis planning and Iktos Robotics platform, enable us to deliver preclinical candidates in less than 2 years.
Explore our pipeline showcasing the breadth and depth of our ongoing projects.
Methylenetetrahydrofolate dehydrogenase 2
MTHFD2 is a mitochondrial enzyme involved in the folate-mediated one-carbon metabolism pathway. It plays a crucial role in controlling the fate and function of Th17 cells, and its inhibition promotes a Treg cell-like phenotype.
MTHFD2 deficiency has been shown to reduce disease severity in multiple in vivo inflammatory disease models. Pharmacological inhibition of MTHFD2 has the potential to treat various inflammatory conditions with an improved safety profile compared to JAK1 inhibitors.
We have applied our AI-driven drug discovery platforms, Makya and Spaya, to identify novel, potent, and selective MTHFD2 inhibitors. IKT525, a representative molecule from our lead series, is a potent (IC50 < 5nM), selective (>1000X over MTHFD1), and potential first-in-class MTHFD2 inhibitor with desirable drug-like properties. Preclinical candidate nomination is expected by 2025.
Shared Program
How we work
Our drug discovery process integrates the power of AI and robotics at every step, iterating the DMTA cycle to converge on a Preclinical Drug Candidate in less than 2 years.
Our approach is distinguished by superior chemistry-based Generative AI that produces novel, synthesizable molecules optimized in a Structure-Based Drug Design context; and a unique way of bridging the gap between in silico and in vitro through AI-driven automated synthesis enabled by the integration of all our technological assets into a one-of-its-kind platform.
Technologies
Process
Partner with Iktos
Embark with us
Since our inception in 2016, we have consistently delivered value through over 60+ collaborations with leading pharmaceutical, biotech, and academic institutions. Our highly skilled team is dedicated to pushing the boundaries of AI-driven drug design, making us a trusted partner in your molecular odyssey.
get started today
Interested in learning more about our pipeline or collaborating with us?
Contact us to explore partnership opportunities and how we can accelerate your drug discovery efforts.
